Pfenex and Hospira have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection). Read the full story

Retinopathy Partnering report provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Dry Eye Partnering report provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Conjunctivitis Partnering report provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Age-related Macular Degeneration Partnering report provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Glaucoma Partnering report provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

The Ophthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter ophthalmics/ophthalmology partnering deals. Read the full story

Deal analysis by Current Agreements  shows that ophthalmics dealmaking activity has been steady with an average of 68 deals signed since 2009. Read the full story

Merck signed an agreement for Santen Pharmaceutical to purchase Merck’s ophthalmology products. Read the full story

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. Read the full story